Compare STAA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | ARQT |
|---|---|---|
| Founded | 1982 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.9M | 3.3B |
| IPO Year | 1995 | 2020 |
| Metric | STAA | ARQT |
|---|---|---|
| Price | $17.45 | $22.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $22.19 | ★ $34.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 03-03-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | $239,442,000.00 | ★ $376,072,000.00 |
| Revenue This Year | $33.83 | $34.46 |
| Revenue Next Year | $8.16 | $29.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $14.69 | $11.86 |
| 52 Week High | $30.81 | $31.77 |
| Indicator | STAA | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 42.41 | 37.45 |
| Support Level | $17.13 | $22.56 |
| Resistance Level | $18.19 | $27.26 |
| Average True Range (ATR) | 0.92 | 0.92 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 14.29 | 22.56 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.